Company intelligence / Profile preview

Neurenati Therapeutics

Ownership: Private
Employees: ~20
Development stage: Preclinical

Overview

Neurenati’s lead program, NEU-001, is a first-in-class, intrarectal combination therapy using a neurotrophic growth factor to regenerate the enteric nervous system in children with Hirschsprung disease. The company has received both Orphan Drug and Rare Pediatric Disease Designations from the US FDA for NEU-001. IND-enabling preclinical work is ongoing, with plans to initiate clinical trials by late 2025 or early 2026. The goal is to provide a non-surgical curative option that could eliminate the need for invasive surgery and reduce lifelong complications associated with current treatments[1][5][6].

Therapeutic areas: Gastroenterology
Modalities: Growth factors (combination therapy)[6][10]
Industry: Biotech

Drug pipeline

1 asset

NEU-001 (Université du Québec à Montréal)

Preclinical

Partnerships

CQDM-SynergiQc grant support[5]Axelys (IP/licensing management and business coaching)[5]

Beyond the preview

Go deeper on Neurenati Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurenati Therapeutics.

Explore the full profile